Meet the Team
Dr. Her Zhisheng is a biomedical researcher and technology leader, serving as the Chief Scientific Officer of Humlab Global.
With a strong foundation in immunology derived from his tenure at the Agency for Science, Technology and Research (A*STAR)—including roles at the Singapore Immunology Network (SIgN) and the Institute of Molecular and Cell Biology (IMCB)—Dr. Her is an expert in the development of humanized mouse models. His work focuses on advancing preclinical platforms for infectious diseases and cancer immunotherapy, contributions that earned him the T-Up Emerging Talent Award in 2024.
Chief Scientific Officer
Her Zhisheng
Chen Qingfeng
Founder
Dr. Chen Qingfeng is a Senior Principal Investigator at A*STAR’s Institute of Molecular and Cell Biology (IMCB), where he develops advanced humanized mouse platforms to model human immunity and tissue‑specific disease mechanisms. His work supports research in oncology, infectious diseases, autoimmune disorders, and stem‑cell–based therapies, establishing his laboratory as a leader in human‑relevant preclinical modeling.
His research focuses on integrating functional human immune systems and human tissues into mouse models to study human‑specific biological interactions. These platforms enable investigation of immune responses, tissue‑level pathology, and therapeutic mechanisms, and have been applied across cancer biology, viral infections, autoimmunity, and regenerative approaches.
Dr. Chen earned his PhD in Immunology from the University of Science and Technology of China and conducted postdoctoral research at the Singapore‑MIT Alliance for Research and Technology (SMART). He joined IMCB in 2012 and established a dedicated humanized mouse research unit that continues to refine models for studying immune–tissue interactions and evaluating emerging therapeutics.
His humanized mouse systems are widely used in drug discovery and preclinical development, supporting the evaluation of therapeutics in models that better reflect human biology. His contributions include patient‑derived xenograft systems, immunotherapy evaluation models, and infection‑specific platforms published in leading journals.